The firm said that it delivered 27,126 flagship Avise CTD tests, including Avise Lupus, during the recently completed quarter, a 13 percent year-over-year increase.
The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.
The firm is adding data on patient risk for radiographic progression and cardiovascular events to the test, which was recently included in the ACR guidelines.
Following its IPO in September, the company is expanding its presence with increased product offerings in the pipeline and a renewed focus on reimbursement and R&D.
The immunoassays are are indicated for the quantitative determination of IgM RF antibodies and the semi-quantitative determination of IgA RF antibodies.
